Zobrazeno 1 - 10
of 274
pro vyhledávání: '"Kostas N, Syrigos"'
Autor:
Richa Gupta, Sima Zacharek, Robert S. Meehan, Micaela Morgado, Angelo Porciuncula, Kurt A. Schalper, Kostas N. Syrigos, Joshua Frederick
Publikováno v:
Clin Cancer Res
Purpose: To evaluate the tissue distribution and clinical significance of OX40 and OX40L in human non–small cell lung cancer (NSCLC). Experimental Design: Using multiplexed quantitative immunofluorescence, we conducted simultaneous and localized me
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::e99884d173d5208822664c2705fd267b
https://doi.org/10.1158/1078-0432.ccr-21-0987
https://doi.org/10.1158/1078-0432.ccr-21-0987
Autor:
Nuran Katgi, Z. Andric, Elena Poddubskaya, Rita de Cassia Costamilan, Chaiyut Charoentum, Eduardo P Yañez Ruiz, Tamta Makharadze, Andrea Fulop, Susana Millan, D. Trukhin, Ana Del Campo García, Ravi Shankar Bellala, Yamil Alonso Lopez Chuken, Kostas N. Syrigos, Alexandra Paravisini, Amalia Florez, Jasmin Reyes-Igama, Irfhan Ali Hyder Ali, Stella Investigators, Ilieva Rumyana
Publikováno v:
Biodrugs
Background MB02 (bevacizumab biosimilar) showed similar structural, functional, and pharmacokinetic properties to reference bevacizumab (Avastin®; EU-bevacizumab). Objectives To confirm clinical similarity between MB02 and EU-bevacizumab, a comparab
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::118637a30fee9df97cf6260e9dbda61c
http://europepmc.org/articles/PMC8295170
http://europepmc.org/articles/PMC8295170
Autor:
Darko Antic, Isabelle Mahé, Essam AboElnazar, Eleftheria Lefkou, Kostas N. Syrigos, Grigoris T. Gerotziafas, Ismail Elalamy, Hiqmat Abdel-Razeq, Ali T. Taher, Patrick Van Dreden
Publikováno v:
Thrombosis Research. 191:S50-S57
A B S T R A C T Important progress has been made in the development of risk assessment models (RAM) for the identification of outpatients on anticancer treatment at risk of venous thromboembolism (VTE). Since the breakthrough publication of the origi
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::1b5581f8e5d736d3d5a53a96eab771cf
https://doi.org/10.1016/s0049-3848(20)30397-2
https://doi.org/10.1016/s0049-3848(20)30397-2
Publikováno v:
Pharmaceuticals, Vol 5, Iss 11, Pp 1236-1264 (2012)
Lung cancer is the primary cause of cancer-related mortality worldwide and although improvements in treatment have been achieved over the last few years, long-term survival rates for lung cancer patients remain poor. Therefore, there is an imperative
Externí odkaz:
https://doaj.org/article/598a6a920ae24a3fa16a507d6649b901
Autor:
Eric Vicaut, Frederikus A. Klok, Charles Marc Samama, Cecilia Becattini, Isabelle Mahé, Alexander T. Cohen, Giancarlo Agnelli, Menno V. Huisman, Sebastian Szmit, D. Mayeur, Peter Verhamme, Marc Philip Righini, Marc Carrier, Tzu-Fei Wang, Manuel Monreal, Kostas N. Syrigos, Adam Torbicki, Juan J. López-Núñez, Cihan Ay, Céline Chapelle, Anthony Maraveyas, Olivier Mir, Aristotelis Bamias, Philippe Girard, Guy Meyer, Silvy Laporte
Publikováno v:
Thrombosis And Haemostasis
r-IGTP. Repositorio Institucional de Producción Científica del Instituto de Investigación Germans Trias i Pujol
instname
Thrombosis and Haemostasis. GEORG THIEME VERLAG KG
Thrombosis and Haemostasis
r-IGTP. Repositorio Institucional de Producción Científica del Instituto de Investigación Germans Trias i Pujol
instname
Thrombosis and Haemostasis. GEORG THIEME VERLAG KG
Thrombosis and Haemostasis
Cancer-associated thrombosis (CT) is associated with a high risk of recurrent venous thromboembolic (VTE) events that require extended anticoagulation in patients with active cancer, putting them at risk of bleeding. The aim of the API-CAT study (NCT
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::cf569ae999b4487762e45bc2bae70053
https://hdl.handle.net/1887/3280174
https://hdl.handle.net/1887/3280174
Autor:
K Tavernaraki, Garyphallia Poulakou, I. Anagnostopoulos, L Thanos, Kostas N. Syrigos, M K Spanorriga, Styliani Lagou
Publikováno v:
Journal of Thrombosis and Thrombolysis. 49:572-577
Our knowledge about the incidence of pulmonary embolism (PE) and the performance of age adjusted D-dimers (Dd) cutoff amongst patients with lung cancer (LC) and suspected PE, remains limited. We retrospectively analyzed all clinically suspected patie
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::8d0600b470a10cb4ead608937ea8ba40
https://doi.org/10.1007/s11239-019-02003-8
https://doi.org/10.1007/s11239-019-02003-8
Publikováno v:
Lung Cancer. 133:56-61
Inhibitors of the hedgehog pathway are effective in patients with basal cell carcinoma and a subgroup of patients with medulloblastoma with active hedgehog signaling. Despite preclinical work suggesting otherwise, clinical trials in solid tumors of e
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::0db91068b629a2b0af1dee0c486b0899
https://doi.org/10.1016/j.lungcan.2019.05.004
https://doi.org/10.1016/j.lungcan.2019.05.004
Autor:
Igor Bondarenko, Maciej Bryl, Kazuo Kasahara, Vladimir Ivanovich Vladimirov, Manuela Zereu, Kostas N. Syrigos, Niels Reinmuth, Angel H. Bair, Fiona Hilton, K. F. Liau
Publikováno v:
Biodrugs
Background PF-06439535 is a bevacizumab biosimilar. We aimed to compare the efficacy and safety of PF-06439535 with that of reference bevacizumab (Avastin®) sourced from the EU (bevacizumab-EU), each with paclitaxel and carboplatin, in the first-lin
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::0f099407cf16dc9bb34589c8cf50fdc8
http://europepmc.org/articles/PMC6790355
http://europepmc.org/articles/PMC6790355
Autor:
Kotoula, Ioannis Efstratiou, E Res, Sofia Lampaki, Paris Kosmidis, Despoina Televantou, Kyriaki Papadopoulou, G. Fountzilas, Emily Daskalaki, X. Mavropoulou, Grigorios Rallis, H. Linardou, Karavasilis, Samantas E, Anna Kalogera-Fountzila, Dimitrios Pectasides, Kostas N. Syrigos, George Kouvatseas, Thomas Zaramboukas, Mountzios G
Publikováno v:
Cancer Genomics - Proteomics. 16:531-541
Background/Aim: KRAS mutations are reported in 20-25% of non-small cell lung cancer (NSCLC) and their prognostic role is unclear. We studied KRAS and EGFR genotyping in Greek NSCLC patients. Patients and Methods: KRAS and EGFR genotypes were centrall
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::eb6f2558d5481bb97faf0fda0515c144
https://doi.org/10.21873/cgp.20155
https://doi.org/10.21873/cgp.20155
Autor:
Marousa Kouvela, Maria Grammoustianou, Foteini Sarropoulou, Maria Mani, Ioannis Gkiozos, Kostas N. Syrigos
Publikováno v:
Journal of Clinical Oncology. 40:e13531-e13531
e13531 Background: It is known that malignancies exaggerate the risk of thrombosis up to 20%, while for Lung Cancer (LC) is articulated up to 14%. Likewise, thrombosis amplifies the LC progression, thrombosis-associated lung cancer (TALC). The pathop
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::566c71e2a0a79edd3584203bc5d027bc
https://doi.org/10.1200/jco.2022.40.16_suppl.e13531
https://doi.org/10.1200/jco.2022.40.16_suppl.e13531